Bio-economy news

Subscribe to Bio-economy news feed Bio-economy news
Business Wire - The global leader in news distribution
Updated: 29 min 15 sec ago

NAMSA and NAGLREITER Partner to Provide Innovative Development Solution to Global Medical Device Manufacturers

10 hours 31 min ago
TOLEDO, Ohio & FT. LAUDERDALE, Fla.--(BUSINESS WIRE)--#clinicalresearch--NAMSA®, the world’s only Medical Research Organization (MRO®) that accelerates medical device development through integrated laboratory, clinical and consulting services, is pleased to announce its partnership with NAGLREITER™ Medical Device Development Organization (MDDO), a high-growth medical device design, development and manufacturing firm. For nearly 50 years, NAMSA has focused on offering the most critical services required to acceler

Stuart Raetzman Appointed CEO of Nestlé Skin Health

14 hours 31 min ago
LAUSANNE, Switzerland--(BUSINESS WIRE)--Nestlé has appointed Stuart Raetzman as CEO of Nestlé Skin Health, effective immediately. “I am very pleased that Stuart will be leading Nestlé Skin Health as CEO. Nestlé’s purpose is to enhance quality of life and contribute to a healthier future. Under Stuart’s leadership, Nestle Skin Health will support our overall mission,” says Mark Schneider, CEO of Nestlé. Stuart is a healthcare professional with over 25 years’ experience. He previously held senior

CSols, Inc. Enhances and Extends GenoLogics Clarity LIMS for Adaptive Biotechnologies

Fri, 19/05/2017 - 15:38
NEWARK, Del.--(BUSINESS WIRE)--Adaptive Biotechnologies decided to upgrade its GenoLogics Clarity LIMS and turned to CSols, a Clarity Certified Application Development, for the enhancements, extensions, and interfaces.

BioVectra Inc. to Open New Microbial Fermentation and Complex Chemistry Site in December 2017

Thu, 18/05/2017 - 12:30
WINDSOR, Nova Scotia--(BUSINESS WIRE)--BioVectra Inc., a Contract Development and Manufacturing Organization (CDMO) providing cGMP services to globally operated biotech and pharmaceutical companies, today announced that its fourth cGMP facility will be fully operational by December 2017. The late-stage to commercial-scale microbial fermentation and complex chemistry facility is located in Windsor, Nova Scotia, with proximity and service to Northeast USA development entities. BioVectra’s $30 mil

Zymeworks to Present at the 2017 American Society of Clinical Oncology Annual Meeting

Wed, 17/05/2017 - 17:26
VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (“Zymeworks”), a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer, today announced that it will be presenting Phase 1 clinical trial dose escalation data at the American Society of Clinical Oncology (“ASCO”) Annual Meeting, being held from June 2-6, 2017 in Chicago, Illinois. The presen

Aurinia Doses First Patient in AURORA Phase 3 Clinical Trial of Voclosporin in Lupus Nephritis

Wed, 17/05/2017 - 16:27
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced that the first patient has been dosed in AURORA, the Company’s Phase 3 confirmatory clinical trial evaluating voclosporin for the treatment of lupus nephritis (LN), an autoimmune disease caused by lupus that involves extreme inflammation and failure of the kidneys. “Dosing

Novelogics Biotechnology, Inc. & CDRD Partner to Advance Novel Cancer Treatment

Wed, 17/05/2017 - 10:24
VANCOUVER, British Columbia--(BUSINESS WIRE)--#biotech--Novelogics Biotechnology, Inc. announced today that it has entered into a research agreement with CDRD to further characterize Novelogics' internally-developed antibody immunotherapy.

Leading Bioscience Entrepreneurs and Leaders Tackle the “Anchor Company” Challenge

Wed, 17/05/2017 - 08:23
TORONTO--(BUSINESS WIRE)--TORONTO May 17th 2017 - The Ontario Bioscience Innovation Organization (OBIO®) releases a report on actionable strategies to establish a world-leading bioscience industry in the province of Ontario.

Covalon Engages Advisors to Pursue Strategic Acquisitions

Tue, 16/05/2017 - 07:20
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced that it has engaged MPA Morrison Park Advisors Inc. (“MPA”) as a financial advisor to help the Company accelerate its growth and expansion by pursuing strategic acquisitions and enhance the Company’s profile in the capital markets and investment community. As partial compensation for the services to be provided, the Company has agre

Boehringer Ingelheim Inaugurates World-Class Biopharmaceutical Manufacturing Facility in China

Tue, 16/05/2017 - 02:18
INGELHEIM, Germany & SHANGHAI--(BUSINESS WIRE)--Today, Boehringer Ingelheim inaugurated its commercial production site for biopharmaceuticals in Zhang Jiang Hi-tech Park of Shanghai (China). The site, with the first-phase investment of more than €70 million, is the first and only biopharmaceutical facility established by a leading multinational active biopharmaceutical manufacturer in China utilizing mammalian cell culture technology. With its global network of biopharmaceutical production site

Alternate Health Provides Clarification Update on Continuing Medical Education Courses

Mon, 15/05/2017 - 17:15
TORONTO--(BUSINESS WIRE)--Alternate Health Corp (CSE:AHG) (OTC:AHGIF), a leader in complementary medicine and patient-focused healthcare, today announced an update and clarification on the first-ever Continuing Medical Education (CME) course approved for AMA PRA Category 1 Credit(s)TM regarding treatments of Chronic Traumatic Encephalopathy (CTE), including Cannabis. This course has been created in accordance with the accreditation requirements and policies of the Accreditation Council for Cont

Zymeworks Reports First Quarter 2017 Financial Results

Mon, 15/05/2017 - 16:15
VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (“Zymeworks”) (NYSE: ZYME; TSX: ZYME) a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer, today reported financial results for the first quarter ended March 31, 2017. “During the first quarter, among other highlights, we received top-line data from the dose escalation stage of our on-go

Aurinia Reports First Quarter 2017 Financial Results, Announces Initiation of Phase III Aurora Clinical Trial, and Provides Operational Highlights

Mon, 15/05/2017 - 08:13
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Reports First Quarter 2017 Financial Results, Announces Initiation of Phase III Aurora Clinical Trial, and Provides Operational Highlights

ARTMS Products Inc. Partners with Alliance Medical to Modernize, Stabilize UK Medical Isotope Supply Chain

Mon, 15/05/2017 - 08:13
VANCOUVER, British Columbia--(BUSINESS WIRE)--ARTMS Products Inc. collaborates with Alliance Medical Group in the area of radiopharmaceuticals and isotope production via medical cyclotrons.

Biogen Acquires Remedy Pharmaceuticals’ CIRARA™ for Large Hemispheric Stroke

Mon, 15/05/2017 - 08:13
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen (NASDAQ: BIIB) announced today that it has completed an asset purchase of Remedy Pharmaceuticals’ Phase 3 candidate, CIRARA™ (intravenous glyburide). The target indication for CIRARA is large hemispheric infarction (LHI), a severe form of ischemic stroke where brain swelling (cerebral edema) often leads to a disproportionately large share of stroke-related morbidity and mortality. The U.S. Food and Drug Administration (FDA) recently granted CIRARA Orpha

Acerus Reports First Quarter 2017 Financial Results

Fri, 12/05/2017 - 17:55
TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (TSX: ASP) today reported its financial results for the three month period ended March 31, 2017. Unless otherwise noted, all amounts are in U.S. dollars. “The Canadian launch of Natesto® is off to a very strong start and prescriptions in the U.S. have been accelerating at an increased rate over the last weeks,” says Tom Rossi. “We have also begun to prepare for the launch of GynoflorTM in Canada which, if approved, could be an importa

Antibe Therapeutics Engages Topstone Research and Appoints Dr Francis Chan as Key Advisor for Phase 2 Clinical Trial of ATB-346

Fri, 12/05/2017 - 07:53
TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Engages Topstone Research and Appoints Dr Francis Chan as Key Advisor for Phase 2 Clinical Trial of ATB-346

Covalon Announces $2.6 Million Private Placement and Warrant Exercise

Fri, 12/05/2017 - 07:53
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV:COV), an advanced medical technologies company, today announced that the Company intends to raise an aggregate of approximately $2,600,000, of which approximately $1,825,000 stems from a non-brokered private placement (the “Offering”) and $775,000 from the exercise of currently outstanding warrants. The Offering comprises approximately 931,121 units at a price of $1.96 per unit for aggregate gros

Zymeworks to Present at UBS Global Healthcare Conference

Fri, 12/05/2017 - 07:53
VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (“Zymeworks”) (NYSE:ZYME; TSX:ZYME) a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer, today announced it will present at the 2017 UBS Global Healthcare Conference. Conference Details: Event:     UBS Global Healthcare Conference Date/Time: May 23, 2017 at 11:30 a.m. EDT Location: New Y

Pages